Genetic or pharmacological inhibition of either of these components (sPLA2-III, ATX, LPA1, VCAM-1, ITGB2/3, IL-33, L-PGDS, or DP1) hampers mast cell maturation and thereby prevents allergic reaction. Here, PLA2G3 is linked to allergic disease.